乳腺癌辅助放疗后甲状腺体积变化
该回顾性研究分析了2007至2019年间61例接受锁骨上区区域淋巴结照射的乳腺癌患者,发现治疗后6个月起甲状腺体积即出现下降,4年平均下降29.7%,且甲状腺功能减退发生率为27.9%;发生甲减者接受20至40 Gy照射的甲状腺亚体积在12个月时下降更明显。
要点
- 锁骨上区放疗后6个月即可见甲状腺体积缩小,4年平均缩小29.7%。
- 甲状腺功能减退发生率为27.9%(17例)。
- 发生甲减者20至40 Gy亚体积在12个月时下降更显著(p=0.033)。
核心结论
- 本研究首次显示乳腺癌锁骨上区放疗后最早6个月即可观察到甲状腺体积缩小,且与临床和亚临床甲减的发生相关。
- 乳腺癌锁骨上区放疗后甲状腺亚体积缩小与剂量存在剂量依赖性关联。
- 作者认为,在可行情况下应努力降低接受区域淋巴结照射乳腺癌患者的甲状腺剂量。
研究设计与样本
- 回顾性分析2007至2019年间接受锁骨上区放疗且符合纳入标准的61例乳腺癌患者。
- 在CT模拟定位及随访图像上回顾性勾画甲状腺,分析个体剂量体积直方图以确定特定等剂量线内外的甲状腺体积。
- 通过将放疗后扫描与CT模拟定位融合,估算基于不同放疗剂量的甲状腺相对体积变化。
- 采用逻辑回归评估甲状腺体积变化作为甲减发生因素的作用。
主要发现
- 治疗前甲状腺体积中位数为11.8 cc(范围6.3-74.1 cc),其中42.2%位于20 Gy等剂量线内,23.2%位于40 Gy等剂量线内。
- 治疗后1年甲状腺体积显著下降(p < 0.0001),此后持续下降。
- 至治疗后4年,甲状腺体积平均下降29.7%(范围2.3-64.4%)。
- 接受40 Gy或更高剂量的甲状腺体积下降幅度大于接受较低剂量者。
- 17例患者发生甲减(27.9%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Incidental thyroid gland irradiation frequently occurs in breast cancer patients who receive regional nodal irradiation (RNI) to the supraclavicular (SCV) region. Recent studies suggest hypothyroidism (HT) is a complication of radiation therapy (RT) that includes SCV fields. We retrospectively analyzed patients who received RNI to evaluate thyroid gland evolution following RT as well as its association with the development of HT. MATERIALS AND METHODS: 61 breast cancer patients received SCV-directed RT between 2007 and 2019 and met inclusion criteria. Thyroid glands were retrospectively contoured on CT simulation and follow-up images. Individual dose-volume histograms were analyzed to determine thyroid volume within and outside specific isodose lines. Relative thyroid volume changes based on different radiation doses were estimated by fusing post-RT scans with CT simulation. Logistic regression was performed to assess thyroid volume changes as a factor in the development of HT. RESULTS: Median pre-treatment thyroid volume was 11.8 cc (range: 6.3-74.1 cc) with a median of 42.2 % within the 20 Gy and 23.2 % within the 40 Gy isodose lines. A significant decrease in thyroid volume was noted by 1-year post-treatment (p < 0.0001) and thereafter. By 4 years post-treatment, average thyroid volume was decreased by 29.7 % (range: 2.3-64.4 %). Thyroid volume receiving 40 Gy or higher demonstrated a greater decrease compared to those receiving lower irradiation dosage. HT occurred in 17 patients (27.9 %). Patients who developed HT displayed a larger decrease in the thyroid volume receiving between 20 and 40 Gy at 12 months (p = 0.033). CONCLUSION: Our study demonstrates for the first time that a reduction in thyroid volume may be seen as early as 6 months after SCV-directed RT for breast cancer, which correlates with development of clinical and subclinical HT. Furthermore, a dose-dependent correlation exists between thyroid subvolume reduction and SCV-directed RT in breast cancer patients. As feasible, efforts should be made to reduce the dose to the thyroid in patients who undergo RNI for breast cancer.
引用
- Roberson J, Huang H, Noldner C, et al. Thyroid volume changes following adjuvant radiation therapy for breast cancer. Clin Transl Radiat Oncol. 2022. PMID: 36582422. doi:10.1016/j.ctro.2022.100566
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。